Immune drug studied in thyroid cancer before surgery
NCT ID NCT05852223
First seen May 01, 2026 · Last updated May 14, 2026 · Updated 4 times
Summary
This study tests the drug pembrolizumab in people with high-risk thyroid cancer before they have surgery. The goal is to see how the drug affects immune cells in the tumor and blood. About 25 adults will take part. This is a phase 2 trial, so it is still early, but it may help doctors understand if this approach could improve treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFERENTIATED THYROID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istituti Clinici Scientifici Maugeri
RECRUITINGPavia, Lombardy, 27100, Italy
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.